HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Erratum (v30,p2421) All Versions of this Article: dc06-1551v1 dc06-1551v2 30/6/1351    most recent Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schmieder, R. E. Articles by Ruilope, L. M. Search for Related Content PubMed PubMed Citation Articles by Schmieder, R. E. Articles by Ruilope, L. M. Social Bookmarking                What's this?

Impact of Telmisartan Versus Ramipril on Renal Endothelial Function in Patients with Hypertension and Type 2 Diabetes

¹Department of Nephrology and Hypertension, University of Erlangen-Nürnberg, Erlangen, Germany
²Department of Medicine, University of Montpellier, Montpellier, France
³Department of Nephrology and Arterial Hypertension, Hôpital E Herriot, Lyon, France
⁴Hypertension Unit, 12 de Octubre Hospital, Madrid, Spain

roland.schmieder{at}rzmail.uni-erlangen.de

ABSTRACT

Background:: One of the earliest signs of vascular change is endothelial dysfunction, which is also known to provoke albuminuria and to predict cardiovascular prognosis. The study aimed to analyze the effects of renin-angiotensin-system (RAS) blockade on renal endothelial function.

Methods:: In a multicenter, prospective, double-blind, forced-titration, randomized study, 96 patients with type 2 diabetes, hypertension, GFR >80 mL/min, and normo- or microalbuminuria were treated once daily with telmisartan 40/80 mg or ramipril 5/10 mg for 9 weeks.

Results:: The (mean ± SE) fall in renal plasma flow (RPF) in response to intravenous NG-monomethyl-L-arginine (L-NMMA), reflecting the magnitude of nitric oxide (NO) activity, increased with telmisartan from 71.9 ± 9.0 mL/min before therapy to 105.2 ± 9.7 mL/min at end of treatment (p < 0.001). With ramipril, RPF response to L-NMMA increased from 60.1 ± 12.2 mL/min to 87.8 ± 9.2 mL/min (p = 0.018). The adjusted mean ± SE difference between treatments was -17.1 ± 13.7 mL/min (p = 0.214). In accordance, telmisartan increased RPF at rest (i.e., without L-NMMA) from 652.0 ± 27.0 mL/min to 696.1 ± 31.0 mL/min (p = 0.047), whereas ramipril produced no significant changes in RPF. The more the basal NO activity improved, the greater was the vasodilatory effect on renal vasculature (r = 0.47, p < 0.001).

Conclusions:: In patients with type 2 diabetes telmisartan and ramipril both increased NO activity of the renal endothelium significantly that in turn may support the preservation of cardiovascular and renal function.

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				G. Grassi, F. Quarti-Trevano, and G. Mancia Review: Cardioprotective effects of telmisartan in uncomplicated and complicated hypertension Journal of Renin-Angiotensin-Aldosterone System, June 1, 2008; 9(2): 66 - 74. [Abstract] [PDF]